Live feed07:30:00·3dSave storyPRReleasevia QuantisnowTuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell CarcinomaByQuantisnow·Wall Street's wire, on your screen.HURATuHURA Biosciences Inc.Health Care